Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Are these associations with infection, biomarkers and weather real or imaginary? Linked or luck? Causal or casual? You decide....
Dr. John Cush RheumNow
2 years 5 months ago
Join our experts, Drs Liebowitz and Mehta, as they provide insights on the differential diagnosis and management concepts in autoinflammatory diseases.
https://t.co/FJtWtaxXeG https://t.co/olcRoFZrBY
Dr. John Cush RheumNow
2 years 5 months ago
Metabolic signature for fibromyalgia? Study of 54 FM & 31 controls w/ Machine learning to identify 13 metabolic markers that predicted FM w/ 79% accuracy; levels of 5-hydroxyindole-3-acetic acid & glutamine correlated w/ fatigue. https://t.co/YAjffGVATG https://t.co/5UWNpDNioT
Dr. John Cush RheumNow
2 years 5 months ago
As of 11/23, FDA has approved 44 biosimilars to 14 different reference products. FDA systematic review on biosimilars found no differences in the risk of death, serious adverse events, or treatment discontinuations between the switch and no-switch arms.https://t.co/yVScZnP559 https://t.co/feswD1gJz9
Despite the availability of numerous advanced therapies for psoriatic arthritis (PsA), there remains a substantial burden and unmet need for improved therapies, according to a newly published Canadian study.
A multinational study of polyarteritis nodosa (PAN) through the international GLOBAL-PAN network shows PAN to be a complex, multisystem disorder with a high risk of relapse and low risk of death (11% at 10 years).
Dr. John Cush RheumNow
2 years 5 months ago
In 2023, the FDA approved 956 generic drugs and issued 1,493 complete response letters; an improvement on 2022’s 914 approvals and 1,775 complete response letters. https://t.co/XnpQLbxJCr https://t.co/zzf63G4s2R
Dr. John Cush RheumNow
2 years 5 months ago
IBD extraintestinal & joint manifestations - systematic review of 61 studies (13,806 pts) found 8% new joint findings during advanced therapy (no signif difference betw vedolizumab (9%) & ustekinumab (6%). https://t.co/drFAtBG4ZU https://t.co/N8ixHS64HD
Dr. John Cush RheumNow
2 years 5 months ago
Mastery of knee arthrocentesis for internal medicine resident
Brian D. Jaros, MD, presents his poster at RWCS 2024.
https://t.co/xFoEGnj2QH https://t.co/DpW07jJTLf
A UK population cohort study has shown that gout carries an increased risk for a wide variety of cardiovascular disorders.
A matched case–control study examined the electronic health records from the UK Clinical Practice Research Datalink and compared gout (one to five) with controls matched for age, sex, socioeconomic status, geographical region, and calendar, to look a the incidence of 12 cardiovascular diseases.
Dr. John Cush RheumNow
2 years 5 months ago
EGPA: Benralizumab (BEN) or Mepolizumab (MEP)
A multicenter, double-blind, phase 3, randomized, active-controlled trial has shown that BEN was noninferior to MEP for the induction of remission of patients with relapsing or refractory EGPA.
https://t.co/1F8hBCOaFV https://t.co/smTSIY1HA3
Dr. John Cush RheumNow
2 years 5 months ago
Behçet’s Syndrome
A comprehensive overview of Behcet's syndrome appeared in last week's NEJM, reviewing the numerous advances in the immunogenetics, syndrome recognition, and targeted therapeutic approaches.
https://t.co/sLgoCRAavP https://t.co/NibyFpPzmW
Dr. John Cush RheumNow
2 years 5 months ago
Neonatal Fc receptor mAb (lowers Igs) development:
2021 FDA approved efgartigimod (Vyvgart) for myasthenia gravis
2023 FDA approved rozanolixizumab (Rystiggo) for MG
2023 nipocalimab promising efficacy in RA, Sjogrens, hemolytic anemia, MG
INTERESTING? https://t.co/Ou9An9EvUK https://t.co/XDDELNAYYD
